#AI Technology #Perimeter Medical #Cancer Surgery

Perimeter Medical Imaging AI Reports Financial Results for 2024

Perimeter Medical Imaging AI, Inc. is making waves in the medical technology field as it announces its financial results for the fourth quarter and full year of 2024, alongside significant corporate updates. Headquartered in Toronto and Dallas, Perimeter is known for its cutting-edge technology that aims to enhance cancer surgery through advanced imaging tools.

Highlights from the Fourth Quarter and Year-End Results

The results indicate a strong upward trajectory in the company's performance. In the fourth quarter of 2024, Perimeter reported revenues exceeding $293,000, reflecting a remarkable 303% increase compared to the same period last year. This growth is largely attributed to the successful deployment of its FDA-cleared product, the Perimeter S-Series OCT system, which has seen nine new placements in 2024, up from three in 2023.

Furthermore, the company has made substantial strides in the development of its next-generation Perimeter B-Series OCT system, which incorporates proprietary AI technology. The completion of a pivotal study aimed at securing FDA Premarket Approval for the B-Series OCT is a noteworthy achievement. This study demonstrated a statistically significant reduction in the presence of residual cancer during breast-conserving surgeries (BCS), enhancing surgical outcomes.

Expanding Market Penetration

Notably, Perimeter's innovations are gaining traction in hospitals across the U.S., with CHRISTUS St. Vincent in New Mexico being the first to employ the S-Series OCT technology for tissue margin visualization during surgeries. Similarly, Covenant Health Fort Sanders Regional in Tennessee has become the first hospital in that state to implement this groundbreaking technology.

The company also announced that its shares have begun trading on the OTCQX® Best Market under the symbol